In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam | Zendy

Abigail M Rubio | Zendy; Ellen G Kline | Zendy; Chelsea E Jones | Zendy; Liang Chen | Zendy; Barry N. Kreiswirth | Zendy; M. Hong Nguyen | Zendy; Cornelius J. Clancy | Zendy; Vaughn S. Cooper | Zendy; Ghady Haidar | Zendy; Daria Van Tyne | Zendy; Ryan K. Shields | Zendy

Open Access

In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam

Author(s) -

Abigail M Rubio,

Ellen G Kline,

Chelsea E Jones,

Liang Chen,

Barry N. Kreiswirth,

M. Hong Nguyen,

Cornelius J. Clancy,

Vaughn S. Cooper,

Ghady Haidar,

Daria Van Tyne,

Ryan K. Shields

Publication year - 2021

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00084-21

Subject(s) - pseudomonas aeruginosa , tazobactam , microbiology and biotechnology , multiple drug resistance , in vitro , antibiotics , medicine , biology , bacteria , piperacillin , genetics

We compared the in vitro susceptibility of multidrug-resistant Pseudomonas aeruginosa isolates collected before and after treatment-emergent resistance to ceftolozane-tazobactam. Median baseline and postexposure ceftolozane-tazobactam MICs were 2 and 64 μg/ml, respectively. Whole-genome sequencing identified treatment-emergent mutations in ampC among 79% (11/14) of paired isolates. AmpC mutations were associated with cross-resistance to ceftazidime-avibactam but increased susceptibility to piperacillin-tazobactam and imipenem. A total of 81% (12/16) of ceftolozane-tazobactam-resistant isolates with ampC mutations were susceptible to imipenem-relebactam.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research